Figure 2.

Agonistic PD-1 treatment inhibits WTD-induced increase in circulating monocytes. (A) Experimental setup. Ldlr^−/− mice were fed a WTD for 6 weeks while receiving an agonistic PD-1 antibody (n = 15) or control vehicle (n = 14). (B) Weight and serum cholesterol levels were assessed before, during and after treatment. Total monocytes (CD11b⁺Ly6G⁻Ly6C⁺), inflammatory monocytes (CD11b⁺Ly6G⁻Ly6C^high) and patrolling monocytes (CD11b⁺Ly6G⁻Ly6C^int) were measured by flow cytometry in peripheral blood (C) and spleen (D). Mean ± SEM are shown. Statistics was performed using unpaired T-test. P ≤ 0.05 are considered significant. *p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001.